Odprti razpisi › Horizon Europe
Development of innovative antimicrobials against pathogens resistant to antimicrobials
Horizon Europe · Cluster 1 – Health · HORIZON-HLTH-2027-01-DISEASE-08
Funding to bring innovative antibacterial and antifungal candidates against resistant pathogens into clinical trials.
O čem je ta razpis?
The topic funds research and innovation projects that take existing antibacterial and antifungal candidates against selected resistant pathogens into clinical safety and efficacy studies.
Kaj ta razpis financira?
Scope
The topic funds the development of existing innovative antibacterial and antifungal candidates, including antibody-based therapies, that meet at least one of the four WHO innovation criteria: new chemical class, new target, new mode of action, or no evidence of cross-resistance. Phage therapies are excluded. The work supports the European Medical Countermeasures Strategy and the forthcoming Critical Medicines Act.
Each proposal should explicitly state which one of the following pathogens it targets, and the work should address only that pathogen:
- carbapenem-resistant Acinetobacter baumannii (CRAB);
- carbapenem-resistant Enterobacterales (CRE) and third-generation cephalosporin-resistant Enterobacterales (C3GRE);
- carbapenem-resistant Pseudomonas aeruginosa;
- methicillin-resistant Staphylococcus aureus (MRSA);
- drug-resistant Aspergillus fumigatus;
- drug-resistant Candida species.
Research areas
Proposals should address all of the following:
- where necessary, completing in-vivo tests in at least one animal model, or in humanised immune system models, and in non-human primates if regulators require it;
- production of GMP batches of the most promising candidates;
- clinical safety and efficacy studies in humans with a clear regulatory pathway to market authorisation.
Projects should engage with regulators in good time and build on initiatives such as the European Partnership on One Health Antimicrobial Resistance.
Expected outcomes
Better understanding of and access to new products against resistant bacteria and fungi, and candidate therapies available for clinical use in the fight against antimicrobial resistance.
Kaj morate o razpisu vedeti na kratko?
- Proračun teme
- 44.200.000 €
- Najnižji znesek na projekt
- 8.000.000 €
- Najvišji znesek na projekt
- 10.000.000 €
- Oznaka razpisa
- HORIZON-HLTH-2027-01-DISEASE-08
- Program
- Horizon Europe
- Funder
- European Union, Horizon Europe
- Expected number of projects
- 5
Kdo se lahko prijavi na ta razpis?
- Candidates should meet at least one of the four WHO innovation criteria; phage therapies are excluded.
- Participation of third countries where the targeted pathogens are endemic or where outbreaks have occurred or are ongoing is encouraged.
- The participation of start-ups, micro, small and medium-sized enterprises is encouraged.
- Applicants should describe their clinical studies in the dedicated annex using the template in the submission system.
Preverite upravičenost in kako se vaš projekt ujema z razpisom
V brezplačnem računu za vašo organizacijo preverimo pogoje upravičenosti v razpisni dokumentaciji in ocenimo, kako dobro se vaš projekt ujema s tem razpisom.
Kdaj je rok za oddajo?
17. februarja 2027 (104 dni)
13 April 2027 (single-stage call).
Vas razpis zanima? Povzetek je pripravila umetna inteligenca iz uradne razpisne dokumentacije. Podrobnosti se lahko razlikujejo, zato pred prijavo preverite uradno stran razpisa. Pred odločitvijo preberite uradno razpisno dokumentacijo. Zavezujoče je vedno uradno besedilo.
Vir: portal EU Funding & Tenders in uradna razpisna dokumentacija. Uradna stran razpisa Zadnja posodobitev: 6. oktobra 2026.